Clinical Trials and Research

AbstractCardiac amyloidosis (CA) is an infiltrative myocardiopathy caused by extracellular deposits of misfolded proteins, with evolution to heart failure (HF) and…

Findings from several studies presented at ESC Heart Failure Congress 2026 in Barcelona, Spain, were simultaneously published in JACC and JACC: Heart Failure,…

Background & AimCardiac amyloidosis is an infiltrative cardiomyopathy associated with significant morbidity and mortality. Frailty, a biologic syndrome of…

Cardiac amyloidosis is a condition where abnormal protein deposits build up in the heart, making it stiff and causing it to work less effectively. One common type…

− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart…

The US Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug (PRX004) for the treatment of transthyretin-mediated amyloid…

BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), significantly reduces serum transthyretin variability and…

Light chain (AL) amyloidosis is caused by misfolded light chains depositing in tissues in the form of fibrils, leading to organ damage  [1]. Treatment consists…

1 IntroductionSystemic light chain amyloidosis (AL) occurs due to a clonal plasma cell dyscrasia, typically with multi-system involvement and associated with a poor…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults.…